D ecisions regarding the management of anticoagulation in patients with prosthetic heart valves undergoing noncardiac surgery present a difficult balance between the risks of thromboembolism and the risks of bleeding. Cost may be a significant additional factor, given the expense of interventions that may involve hospitalization for heparin therapy during the perioperative period or the use of low-molecularweight heparin. As the rate of embolic events is quite low, on the order of 10 -4 per day, 1 and the period of increased risk is very short, one might anticipate that the cost of preventing these rare events would be great. 2 As Dunn and his colleagues have pointed out in their decision analysis of the "Perioperative Management of Patients on Oral Anticoagulants" in this issue of Medical Decision Making, numerous strategies may be considered. 3 Having discontinued warfarin, should we admit such patients prior to planned surgery for treatment with intravenous heparin, awaiting a normal international normalized ratio (INR)? If so, for how many days? What should we do postoperatively? Should we again "heparinize" them, as inpatients, until they are adequately anticoagulated with oral agents? Can we "bridge" the subtherapeutic period of anticoagulation with low-molecular-weight heparin (LMWH) in the outpatient setting?
This topic has been the subject of great controversy and numerous reviews. [4] [5] [6] [7] [8] [9] No doubt, the controversy is fueled by the absence of adequate randomized controlled trials, forcing choices to be made on the basis of expert opinion, anecdotal reports, the available medical literature, local standards of care, and decision analyses, such as the one performed by Dunn and colleagues, which attempt to synthesize data from multiple disparate sources in an effort to make the best decisions we can despite inadequate data. The most recent American College of Chest Physicians 7th Thrombolytic Conference on Antithrombotic Therapy recommends a variety of approaches tailored to the underlying risk of thrombosis. 10 For patients at low risk of thromboembolism, such as those with bileaflet me-chanical valves in the aortic position, it recommends stopping warfarin approximately 4 days before surgery, allowing the INR to return to near normal, with consideration of a brief course of low-dose unfractionated heparin (UFH) or a prophylactic dose of LMWH postoperatively (if the intervention is associated with a high risk of thrombosis) with the simultaneous reinitiation of warfarin. At the other extreme, in patients at high risk of thromboembolism, such as those with mechanical valves in the mitral position (or oldmodel ball-and-cage valves), it recommends stopping warfarin approximately 4 days before surgery, allowing the INR to return to near normal, and beginning therapy with a full dose of UFH or LMWH as the INR falls (approximately 2 days preoperatively). If preoperative UFH is administered intravenously, it suggests discontinuing the drip approximately 5 h prior to surgery. If subcutaneous UFH or LMWH is used, it recommends discontinuing treatment 12 to 24 h prior to surgery. Postoperatively it recommends commencing low-dose UFH or LMWH and warfarin therapy. Recommendations also are tailored further for patients at low risk of bleeding.
In 1997, Kearon and Hirsh published a review and analysis of management strategies for anticoagulation before and after elective surgery. 6 In particular, they quantified the estimated risks and benefits of the same 2 strategies examined in Dunn's analysis in Medical Decision Making; an aggressive approach in which intravenous heparin is given for 2 days before and 2 days after surgery; and a minimalist approach, under which patients receive no heparin immediately before or after surgery. They estimated that 2 days of intravenous heparin during the postoperative period would increase the absolute rate of major bleeding by about 3%.This estimate was based on a variety of data sources that in-cluded series, many from older studies, [11] [12] [13] examining patients being treated for deep venous thrombosis and pulmonary embolism 1 4 -1 7 as well as carotid endarterectomy. 18 Although the risk of bleeding associated with IV UFH in recent trials of patients with acute venous thromboembolism is less than 3%, it is clear that recent surgery increases this risk. 19 Unfortunately, the magnitude of this increased risk remains uncertain.
More recently, Douketis and colleagues examined LMWH as bridging therapy during the interruption of warfarin. 20 Critical to their protocol was the preprocedural classification of patients as undergoing high-bleeding-risk or non-high-bleeding-risk interventions. Warfarin was stopped 5 days before surgery, and treatment dose LMWH was started 3 to 4 days before surgery. The last dose of LMWH was administered no less than 12 h before surgery. The postoperative anticoagulation regimen was determined on the basis of the bleeding risk associated with the procedure and the adequacy of postprocedure hemostasis. Those at low risk resumed treatment dose LMWH on the day after surgery, whereas warfarin was restarted on the evening of surgery. In high-bleeding-risk patients, warfarin was resumed on the evening after the procedure, whereas these patients did not receive LMWH at any time postoperatively. Six hundred fifty consecutive patients with mechanical heart valves, atrial fibrillation, or history of embolic stroke undergoing elective surgical or other invasive procedures were treated with an LMWH bridging therapy protocol. Thromboemboli occurred in 0.4% and major bleeds in 0.7% of 542 patients who underwent non-high-bleeding-risk procedures. Major bleeding occurred in 1.8% of 108 patients undergoing high-bleeding-risk procedures. In another recent study, Kovacs and colleagues explored a more aggressive bridging therapy with LMWH in a multicentered study of 11 tertiary care hospitals in Canada. Of 224 patients, half had prosthetic valves and half had atrial fibrillation as indications for chronic oral anticoagulant therapy. 2 1 After removing intraoperative bleeding events that occurred before warfarin or dalteparin was restarted, major bleeding occurred in 5 patients (2.2%; 95% CI, 1.0-5.1) within 1 week of surgery. Of note, there were no preoperative events of thrombosis or bleeding in their study, leading them to conclude that "this aspect of the bridging protocol likely does not need modification for this patient population" 21 (p. 166).
Where does this leave the clinician who must make the best decision she can for her patients? First, all patients are not the same. They do not share the same risk of thromboembolism, and their risk of bleeding varies depending on the type of surgical procedure, and pos-sibly their age (>70 years of age) and heparin dose. 19 The risk of thromboembolism in nonanticoagulated patients varies substantially depending on the type of valve, the position of the valve (i.e., mitral, aortic, or both), and other patient characteristics, such as atrial fibrillation, poor ejection fraction, and recent prior thromboembolic event 22 Another factor to be considered is that guidelines for the optimal INR suggest different targets for different types of patients and prosthetic valves 23 : Therefore, the time it takes for patients to become subtherapeutic off anticoagulants and the time it takes to regain therapeutic anticoagulation status after restarting warfarin may vary. Fixed strategies that assume that the temporary discontinuation of warfarin exposes patients to a risk of thromboembolism equivalent to 2 days without anticoagulation before surgery and another 2 days without anticoagulation after surgery may put some patients at increased risk of thromboembolism. Adding one more twist to this complicated story, it recently has been appreciated that polymorphisms of cytochrome P450 CYP2C9 affect the metabolism of warfarin and result in some patients being poor metabolizers of warfarin. 24, 25 Owing to the slower metabolism, these patients are very sensitive to warfarin and have difficulties with the induction of warfarin, with increased variability in their INRs and an increased incidence of bleeding complications. They actually may become therapeutic faster in the postoperative period, but may take longer to become subtherapeutic when discontinuing warfarin preoperatively.
Therefore, as Dunn stated in their systematic review published in 2003, "The decision to pursue an aggressive strategy of perioperative administration of intrave-ECKMAN nous heparin or subcutaneous LMWH should be individualized based on an estimation of the patient's risks of thromboembolism and bleeding and the patient's preferences." 4 Dunn's analysis has added to our understanding of this management dilemma. 3 However, there is still work to be done. Depending on the clinical circumstances, there are a variety of anticoagulation management options to consider. Additional decision and cost-effectiveness analyses examining a broader array of clinical strategies can provide further insights while anticipating results of future clinical studies. It is hoped that such studies will be done to address this management dilemma and the subtleties involved in special-risk populations (e.g., low postoperative bleeding risk, high postoperative bleeding risk, low or high thromboembolic risk, poor metabolizers of warfarin). Strategies that bear further investigation include the following:
1. Only preoperative use of LMWH as bridging therapy; 2. Fewer or greater number of days of intravenous or LMWH preoperatively and postoperatively instead of just 2 days preoperatively and postoperatively; 3. Postoperative heparin not starting until adequate hemostasis (this might vary depending on type of surgery); 4. Postoperative heparin not starting until the 2nd day after surgery rather than starting on the day after surgery (presumably a lower bleeding risk); 5. Consideration of different strategies for special populations: a. In patients with higher targeted INRs (2.5-3.0) who might take longer to become subtherapeutic after stopping warfarin and longer to become therapeutic once more after restarting warfarinmodel a longer time at risk preoperatively and postoperatively and consider strategies that continue heparin for a longer time period; b. In higher bleeding-risk surgeries-only use preoperative heparin; in lower bleeding-risk surgeries-use both preoperative and postoperative heparin.
Although the data regarding bleeding risk are uncertain, Dunn's analysis 3 may be biased toward the minimalist strategy by using higher estimates of bleeding risk based on an older summary analysis 6 and by omitting valve thrombosis as a potential consequence of withholding anticoagulant therapy. 23 In sensitivity analyses, Dunn and colleagues found that the aggressive strategy provided a gain in quality-adjusted life expectancy if the probability of major postoperative hemorrhage was less than 2% (base-case value 3%). 3 More recent studies of tailored LMWH as bridging therapy demonstrate lower risks of perioperative hemorrhage. 20, 21, 26, 27 In analyses using lower bleeding rates and also considering the risk of valve thrombosis, in which there are gains from the "aggressive strategy," albeit small, cost-effectiveness becomes the important driver. In analyses performed more than 1 decade ago, it was estimated that it costs more than $600,000 to prevent a single thromboembolic event in patients with prosthetic heart valves receiving intravenous heparin as bridging therapy. 2, 28 However, these analyses were performed before the availability of LMWH, which allows strategies to be considered that do not require prolonging the preoperative or postoperative hospital stay to ensure the appropriate anticoagulation status. It would be informative to reexamine the cost-effectiveness of the full array of realistic clinical options and circumstances for the management of anticoagulation therapy in this setting.
In closing, most would agree that randomized controlled trials assessing the perioperative use of LMWH in patients with varying indications for long-term anticoagulation are needed to truly answer this clinical question. Until such trials are performed, the debate will undoubtedly continue.
